sar425899 sanofi dual agonist glp-1 glucagon Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes Glucagon-like peptide 1 (GLP-1) -

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

Research suggests that foods, such as eggs, vegetables, and olive oil, may help increase GLP-1 levels

The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults

In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c6.5%

Eligibility criteria Adults (18 years) receiving any approved GLP-1 RA for any indication

Heads of State adopted a new Political Declaration under the 2030 Agenda for Sustainable Development - to reduce premature NCD mortality by one-third by 2030